Cutaneous squamous cell carcinoma (cSCC) is a type of non-melanoma skin cancer (NMSC), which is the most frequently diagnosed skin cancer. Most of the cSCCs are localized and easily treatable, and according to the National Center for Biotechnology Information (NCBI), around 5% of patients experience local recurrence, whereas 4% might develop nodal metastases, and around 2% die due to this disease. Increasing incidence of cutaneous squamous-cell carcinoma is expected to boost the market growth. For instance, according to the Journal of the European Academy of Dermatology and Venereology, an article published in January 2019, reports that in the period 2007-2015, 76,474 people newly diagnosed with squamous-cell carcinoma (SCC) were registered in North Rhine?Westphalia (NRW), with an age?standardized incidence in 2015 of 54 in men, double the rate of 26 in women.
The global cutaneous squamous cell carcinoma treatment market is estimated to be valued at US$ 10,309.76 million in 2020 and is expected to exhibit a CAGR of 7.2% during the forecast period (2020-2027).
Figure 1. Global Cutaneous Squamous Cell Carcinoma Treatment Market Share (%), by Region, 2020
The increasing product development and ongoing trials are expected to propel growth of the global cutaneous squamous cell carcinoma treatment market
Major players in the market are focused on drug development for cutaneous squamous cell carcinoma treatment, which is expected to boost the market growth over the forecast period. for instance, in May 2020, Regeneron Pharmaceuticals, Inc., and Sanofi A.S., collaboratively initiated the clinical trial and announced the longer-term results for Libtayo (cemiplimab-rwlc), PD-1 inhibitor from a pivotal Phase II trial in advanced cutaneous squamous cell carcinoma (cSCC). The data were presented during the virtual 2020 American Society of Clinical Oncology (ASCO) annual meeting.
Report Coverage | Details | ||
---|---|---|---|
Base Year: | 2019 | Market Size in 2020: | US$ 10,309.76 Mn |
Historical Data for: | 2016 to 2019 | Forecast Period: | 2020 to 2027 |
Forecast Period 2020 to 2027 CAGR: | 7.2% | 2027 Value Projection: | US$ 16,867.06 Mn |
Geographies covered: |
|
||
Segments covered: |
|
||
Companies covered: |
Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. |
||
Growth Drivers: |
|
||
Restraints & Challenges: |
|
Figure 2. Global Cutaneous Squamous Cell Carcinoma Treatment Market Share (%), by Treatment, 2020
Increasing approvals for cutaneous squamous cell carcinoma treatment in North America is expected to boost the market growth
North America is expected to hold dominant position in the global cutaneous squamous cell carcinoma treatment market, owing to increasing approvals for cutaneous squamous cell carcinoma treatment in this region. For instance, in June 2020, Merck & Co., Inc., a U.S.-based multinational pharmaceutical company received approval for pembrolizumab (KEYTRUDA) from the U.S. Food and Drug Administration (FDA). The drug is approved for the treatment of recurrent or metastatic cutaneous squamous cell carcinoma (cSCC), which is not curable by surgery or radiation.
Global Cutaneous Squamous Cell Carcinoma Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global Cutaneous Squamous Cell Carcinoma Treatment market during the forecast period.
Key Players
Major players operating in the global Cutaneous Squamous Cell Carcinoma Treatment market include Eli Lilly and Company, Sanofi S.A., Cadila Healthcare Limited, Cipla Limited, Castle Biosciences, Regeneron Pharmaceuticals, Inc., Merck & Co., Inc., Vidac Pharma, LEO Pharma A/S, Regeneron Pharmaceuticals, Inc., Merck Sharp & Dohme, and Amgen Inc. among others.
Cutaneous squamous cell carcinoma (cSCC) is a common type of skin cancer grouped in the class of keratinocyte cancer, or non-melanoma skin cancer. It is derived from cells within the epidermis that make keratin, the protein which makes up skin, hair, and nails. Cutaneous squamous cell carcinoma (cSCC) is an invasive disease, referring to cancer cells that have grown beyond the epidermis. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma.
Market Dynamics
Rising incidence of cutaneous squamous cell carcinoma (cSCC) is expected to drive cutaneous squamous-cell carcinoma treatment market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that squamous cell carcinoma is the second most common form of skin cancer in the U.S followed by basal cell carcinoma. It also reports that over one million squamous cell carcinoma cases are diagnosed in the U.S. each year.
However, lack of standardization in the guidelines for cutaneous squamous cell carcinoma (cSCC) creates a challenge for physicians to execute the treatment, and this is expected to hinder the market growth. For instance, according to the National Center for Biotechnology Information (NCBI), an article published in August 2020, stated that physician's challenge lies in properly assessing a patient's risk for aggressive disease based on tumor or host characteristics.
Key features of the study:
Detailed Segmentation:
“*” marked represents similar segmentation in other categories in the respective section.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients